肝胆相照论坛

标题: APASL2012:5 years of treatment of TNF is associated with Sustained Viral Supprer [打印本页]

作者: StephenW 时间: 2012-2-28 14:34 标题: APASL2012:5 years of treatment of TNF is associated with Sustained Viral Supprer

Five Years of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Associated with Sustained Viral Suppression and Significant Regression of Fibrosis and Cirrhosis

	Reported by Jules Levin 22nd Congress of the Asian Pacific Association for the Study of the Liver (APASL) Feb 16-19, 2012; Taipei, Taiwan E Gane1, N Tsai2, F Weilert3, M Buti4, IM Jacobson5, MK Washington6, BN Bekele7, JD Bornstein7, JF Flaherty7, JG McHutchison7, P Marcellin8 1Auckland City Hospital, Auckland, New Zealand; 2University of Hawaii at Manoa, Honolulu, HI, USA; 3Waikato Hospital, Hamilton, New Zealand; 4Hospital General Universitari Vall d'Hebron and Ciberehd, Barcelona, Spain; 5Medical College of Cornell University, New York, NY; USA; 6Vanderbilt University, Nashville, TN, USA; 7Gilead Sciences Inc., Foster City, CA, USA; 8Hopital Beaujon, Clichy, France

作者: StephenW 时间: 2012-2-28 14:54

本帖最后由 StephenW 于 2012-2-28 14:57 编辑

[attach]285791[/attach][attach]285792[/attach][attach]285795[/attach][attach]285796[/attach][attach]285797[/attach]

作者: StephenW 时间: 2012-2-28 14:58

[attach]285807[/attach][attach]285808[/attach][attach]285809[/attach]

作者: 走遍四方 时间: 2012-2-28 15:33

tks. 有人种来源or基因种类的数据吧

作者: StephenW 时间: 2012-2-28 17:51

回复走遍四方的帖子

The following diagram is from another paper, but I believe it is about the same group of patients (Design study102, 103):

[attach]285837[/attach]

作者: 咬牙硬挺 时间: 2012-2-28 22:55

手机看帖图片看不清楚，麻烦简要讲一下内容吧

作者: 三国杀 时间: 2012-3-12 10:49

我觉得虽然没有大陆的数据，但是，台湾人大部分和大陆人属于一个种系的

所以，替诺福韦在大陆的效果应该是相当的

很期待啊

作者: interdetect 时间: 2012-3-16 17:12

回复 StephenW 的帖子

有没有PDF版的？

作者: StephenW 时间: 2012-3-16 18:07

回复 interdetect 的帖子

我没有。以下是有关于泰诺福韦5年的研究结果:
http://www.natap.org/
APASL: Five Years of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Associated with Sustained Viral Suppression and Significant Regression of Fibrosis and Cirrhosis - (02/27/12)

APASL: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection - (02/27/12)

APASL: Low Baseline Hepatitis B Surface Antigen (HBsAg) Levels and HBV Genotypes B/C are Associated with Persistently Low HBsAg in HBeAg+ Patients Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/27/12)

APASL: Asians have Different Hepatitis B Surface Antigen (HBsAg) Kinetics than Non-Asians while Undergoing Treatment with Tenofovir Disoproxil Fumarate (TDF) or Adefovir (ADV) Followed by TDF up to 192 Weeks - (02/27/12)

APASL: Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/25/12)

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)